Peter Attia

healthlongevitymedicine

Physician focused on longevity and optimal health. Host of The Drive podcast covering healthspan, lifespan, and performance optimization.

Website @PeterAttiaMD

Latest Episodes

GLP-1 drugs fail to slow cognitive decline in Alzheimer’s disease

Peter Attia discusses the disappointing results from clinical trials showing that GLP-1 receptor agonist drugs failed to slow cognitive decline in patients with Alzheimer's disease. Despite the negative findings for treatment of existing Alzheimer's, Attia notes there may still be potential for these drugs in prevention, suggesting that the mechanisms beneficial for metabolic health could help reduce Alzheimer's risk before the disease takes hold.

GLP-1 drugs showed no significant benefit in slowing cognitive decline in Alzheimer's patients despite promising preclinical dataTreatment of established Alzheimer's may be too late for GLP-1 mechanisms to make a meaningful impactPrevention rather than treatment remains a hopeful avenue for GLP-1 drugs in addressing Alzheimer's risk

Feb 21, 2026

Metformin misses the mark?

Peter Attia examines the MET-PREVENT trial, which tested metformin as an anti-aging intervention but produced null results, failing to show significant benefits for preventing age-related disease. He analyzes what went wrong with the trial design and what these findings mean for the broader field of longevity research and the use of metformin as a geroprotective agent. The episode highlights important lessons about how aging intervention trials should be designed and the gap between observational data and randomized controlled trial outcomes.

The MET-PREVENT trial's null results challenge the popular notion that metformin is an effective anti-aging drug for non-diabetic individualsTrial design flaws and endpoint selection may have contributed to the inability to detect meaningful effects of metformin on agingObservational studies suggesting metformin's longevity benefits may not translate to causal effects when tested in rigorous randomized controlled trials

Jan 31, 2026

Navigating the complex relationship between statins, GLP-1, and glycemic control

Peter Attia discusses a study examining the relationship between statin use, the gut microbiome, and blood sugar control, exploring how statins may impact glycemic regulation and interact with GLP-1 pathways. He analyzes the evidence critically and concludes that despite the interesting findings, the study does not warrant any changes to current clinical practice regarding statin prescriptions. The episode emphasizes the complexity of these metabolic interactions while maintaining a practical, evidence-based perspective.

A study linking statins to microbiome changes and blood sugar control is interesting but insufficient to alter clinical practiceThe relationship between statin use and glycemic control involves complex interactions with GLP-1 and gut microbiome pathwaysEvidence-based clinical decision-making should not be swayed by preliminary mechanistic findings without stronger supportive data

Jan 29, 2026

#381 ‒ Alzheimer’s disease in women: how hormonal transitions impact the female brain, the role of HRT, genetics, and lifestyle on risk, and emerging diagnostics and therapies | Lisa Mosconi, Ph.D.

Lisa Mosconi discusses how Alzheimer's disease disproportionately affects women, arguing that hormonal transitions during midlife—particularly menopause—play a critical role in triggering brain changes decades before symptoms appear. She explores how estrogen loss impacts brain energy metabolism and amyloid plaque accumulation, and examines the potential protective role of hormone replacement therapy when initiated at the right time. The conversation also covers genetic risk factors like APOE4, emerging diagnostic tools including brain imaging, and lifestyle interventions that may reduce Alzheimer's risk in women.

Alzheimer's is a disease of midlife that begins decades before symptoms appear, with menopause serving as a critical vulnerability window for women's brain healthHormone replacement therapy may offer neuroprotective benefits when initiated during the perimenopausal transition rather than years after menopauseWomen carry two-thirds of the Alzheimer's disease burden, which cannot be explained by longevity alone and points to sex-specific biological mechanisms

Jan 26, 2026

The absence of atherosclerosis is not an excuse to ignore heart attack symptoms—especially for women

Peter Attia discusses how heart attacks (myocardial infarctions) can occur even in the absence of atherosclerosis, challenging the common assumption that clean arteries mean zero heart attack risk. He emphasizes that women are particularly vulnerable to non-atherosclerotic causes of heart attacks, such as spontaneous coronary artery dissection (SCAD) and coronary vasospasm. The episode serves as a critical reminder that heart attack symptoms should never be dismissed regardless of a patient's atherosclerotic profile, especially in women.

Atherosclerosis is not the only mechanism that can cause a heart attackWomen are disproportionately affected by non-atherosclerotic causes of myocardial infarctionHeart attack symptoms should always be taken seriously regardless of known cardiovascular risk profile

Jan 24, 2026

Get Peter Attia's insights in your inbox

Subscribe and follow Peter Attia to receive weekly AI-curated digests.